KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-cash Items (2018 - 2020)

Esperion Therapeutics' Non-cash Items history spans 3 years, with the latest figure at $72.4 million for Q2 2020.

  • For Q2 2020, Non-cash Items rose 2237.34% year-over-year to $72.4 million; the TTM value through Jun 2020 reached $72.4 million, up 2237.34%, while the annual FY2019 figure was $109.1 million, 3704.52% up from the prior year.
  • Non-cash Items reached $72.4 million in Q2 2020 per ESPR's latest filing, up from $31.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $109.1 million in Q4 2019 to a low of $2.3 million in Q1 2018.
  • Average Non-cash Items over 3 years is $43.4 million, with a median of $47.2 million recorded in 2018.
  • The largest YoY upside for Non-cash Items was 2612.31% in 2019 against a maximum downside of 95.1% in 2019.
  • A 3-year view of Non-cash Items shows it stood at $83.5 million in 2018, then surged by 30.65% to $109.1 million in 2019, then tumbled by 33.61% to $72.4 million in 2020.
  • Per Business Quant, the three most recent readings for ESPR's Non-cash Items are $72.4 million (Q2 2020), $31.1 million (Q1 2020), and $109.1 million (Q4 2019).